Linscomb & Williams Inc. Raises Stake in Eli Lilly and Company (NYSE:LLY)

Linscomb & Williams Inc. increased its stake in Eli Lilly and Company (NYSE:LLYGet Rating) by 2.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,459 shares of the company’s stock after buying an additional 63 shares during the period. Linscomb & Williams Inc.’s holdings in Eli Lilly and were worth $679,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the stock. Capital World Investors raised its stake in Eli Lilly and by 9.8% in the 3rd quarter. Capital World Investors now owns 16,790,382 shares of the company’s stock valued at $3,879,410,000 after acquiring an additional 1,502,363 shares during the period. Geode Capital Management LLC raised its stake in Eli Lilly and by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 14,322,159 shares of the company’s stock valued at $3,300,752,000 after acquiring an additional 357,886 shares during the period. Fisher Asset Management LLC raised its stake in Eli Lilly and by 7.2% in the 4th quarter. Fisher Asset Management LLC now owns 6,982,910 shares of the company’s stock valued at $1,928,820,000 after acquiring an additional 470,522 shares during the period. Morgan Stanley raised its stake in Eli Lilly and by 8.2% in the 2nd quarter. Morgan Stanley now owns 3,822,819 shares of the company’s stock valued at $877,414,000 after acquiring an additional 289,490 shares during the period. Finally, Eaton Vance Management increased its position in shares of Eli Lilly and by 4.3% during the third quarter. Eaton Vance Management now owns 3,476,894 shares of the company’s stock valued at $800,322,000 after buying an additional 142,561 shares during the period. Institutional investors and hedge funds own 82.75% of the company’s stock.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 80,761 shares of the stock in a transaction on Monday, May 16th. The stock was sold at an average price of $302.53, for a total value of $24,432,625.33. Following the completion of the transaction, the insider now owns 105,493,049 shares in the company, valued at $31,914,812,113.97. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Donald A. Zakrowski sold 1,660 shares of the firm’s stock in a transaction on Friday, February 25th. The shares were sold at an average price of $243.84, for a total value of $404,774.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,168,312 shares of company stock valued at $332,138,906. 0.12% of the stock is owned by corporate insiders.

NYSE:LLY opened at $301.40 on Wednesday. The firm has a market cap of $286.38 billion, a PE ratio of 44.65, a price-to-earnings-growth ratio of 2.31 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $193.11 and a fifty-two week high of $314.00. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The business has a 50 day moving average price of $290.78 and a 200-day moving average price of $267.14.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.30. The firm had revenue of $7.81 billion during the quarter, compared to analyst estimates of $7.29 billion. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.87 earnings per share. Research analysts predict that Eli Lilly and Company will post 8.25 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 10th. Investors of record on Monday, May 16th will be issued a dividend of $0.98 per share. The ex-dividend date of this dividend is Friday, May 13th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.30%. Eli Lilly and’s dividend payout ratio is presently 58.07%.

Several equities research analysts have recently weighed in on LLY shares. The Goldman Sachs Group upped their price target on Eli Lilly and from $234.00 to $264.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Daiwa Capital Markets started coverage on Eli Lilly and in a research report on Thursday, March 10th. They set an “outperform” rating and a $286.00 price target on the stock. Morgan Stanley upped their price target on Eli Lilly and from $364.00 to $369.00 in a research report on Friday, April 29th. Bank of America upped their price target on Eli Lilly and from $300.00 to $315.00 in a research report on Thursday, March 17th. Finally, Wells Fargo & Company upped their price target on Eli Lilly and from $280.00 to $305.00 in a research report on Friday, April 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and currently has a consensus rating of “Buy” and an average target price of $302.56.

Eli Lilly and Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.